Evidence map›Paper›PMID 35529676›Full record

ArticleOncoimmunology2022

Novel approach to identify putative Epstein-Barr-virus microRNAs regulating host cell genes with relevance in tumor biology and immunology.

Simon Jasinski-Bergner, Juliane Blümke, Marcus Bauer, Saskia Luise Skiebe, Ofer Mandelboim, Claudia Wickenhauser, Barbara Seliger

Open access · goldAbstract read
In one paragraph

Article in Oncoimmunology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Simon Jasinski-BergnerInstitute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Juliane BlümkeInstitute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Marcus BauerInstitute for Pathology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Saskia Luise SkiebeInstitute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.
Ofer MandelboimDepartment of Immunology, Faculty of Medicine, The Hebrew University of Jerusalem, En Kerem, P.O. Box 12271, Jerusalem 91120, Israel.
Claudia WickenhauserInstitute for Pathology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.ORCID 0000-0002-1807-5575
Barbara SeligerInstitute for Medical Immunology, Martin-Luther-University Halle-Wittenberg, Halle, Germany.ORCID 0000-0002-5544-4958
Martin Luther University Halle-Wittenberg · DEFraunhofer Institute for Cell Therapy and Immunology · DEHebrew University of Jerusalem · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The human Epstein-Barr virus is associated with several human solid and hematopoietic malignancies. However, the underlying molecular mechanisms including virus-encoded microRNAs (miRs), which lead to the malignant transformation of infected cells and immune evasion of EBV-associated tumors, have not yet been characterized. The expression levels of numerous known EBV-specific miRs and their suitability as diagnostic and/or prognostic markers were determined in different human EBV-positive tissues followed by

Indexed as

Burkitt LymphomaEpstein-Barr Virus InfectionsMicroRNAsBiologyCell Transformation, NeoplasticHerpesvirus 4, HumanHumansMicroRNAsEBVEBV-driven diseaseEBV target genesmalignant transformationmicroRNAtranscriptomics

Identifiers

PMID35529676
PMCPMC9067544
OpenAlexW4225285824

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.